DEP-Trastuzumab, page-7

In term of nanomedicine, the main competitor is Abraxane (https://en.wikipedia.org/wiki/Protein-bound_paclitaxel). Abraxane now showed the more advantages in stable compound, which is less side effects and more effect.
The basics of platform of Abraxane is different to dendrimer. Abraxane is based on albumin-bound particle, the whole structure will less stable to support Her2 or any cells signals receptors. I think that is the reason Abraxane is independence outside big pharma worlds.
If SPL can prove the advantages of  dendrimer-drug, we will be crushed and acquired by big boys pharma at any cost.
The most important results of HER2-DEP is more effects than current HER2-antibody therapy.